% | $
Quotes you view appear here for quick access.


  • cytomotw cytomotw Jul 18, 2013 6:47 AM Flag

    GTHP Continues to Await FDA

    The technology seems to be amazing but sales continue to be non-existant in countries where it is being marketed. Is the world's system inexorably tied to the FDA? This stock should be over $1 on the tech alone. GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I agree. The reality is very different. GTHP is dead money until it gets FDA approval. The secondary a couple months ago really hurt the stock. However, the main issue is that we continue to wait for the FDA. FDA is about 2 months late but the technology is impressive. Already approved in Canada and Europe. Company should be at break even (cash flow) late this year. As a result, I do not expect additional dilution. Insiders got warrants and can buy at 68 cents where we have support. Ton of sellers above 70 cents not sure why. I think the risk/reward favor longs. However, be warned.... until FDA you are looking at dead money. The problem is FDA can be tomorrow or 12 months from now.

0.0041-0.0007(-14.58%)Jun 24 3:56 PMEDT